KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other Accumulated Expenses: 2010-2014

Historic Other Accumulated Expenses for Biomarin Pharmaceutical (BMRN) over the last 5 years, with Dec 2014 value amounting to $8.2 million.

  • Biomarin Pharmaceutical's Other Accumulated Expenses rose 161.81% to $9.5 million in Q2 2015 from the same period last year, while for Jun 2015 it was $9.5 million, marking a year-over-year increase of 161.81%. This contributed to the annual value of $8.2 million for FY2014, which is 69.11% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Other Accumulated Expenses stood at $8.2 million for FY2014, which was up 69.11% from $4.9 million recorded in FY2013.
  • Biomarin Pharmaceutical's Other Accumulated Expenses' 5-year high stood at $9.3 million during FY2011, with a 5-year trough of $4.3 million in FY2010.
  • In the last 3 years, Biomarin Pharmaceutical's Other Accumulated Expenses had a median value of $6.2 million in 2012 and averaged $6.4 million.
  • In the last 5 years, Biomarin Pharmaceutical's Other Accumulated Expenses skyrocketed by 113.83% in 2011 and then tumbled by 33.26% in 2012.
  • Biomarin Pharmaceutical's Other Accumulated Expenses (Yearly) stood at $4.3 million in 2010, then spiked by 113.83% to $9.3 million in 2011, then slumped by 33.26% to $6.2 million in 2012, then decreased by 21.10% to $4.9 million in 2013, then spiked by 69.11% to $8.2 million in 2014.